Ansell SM - Search Results

1

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma.

Ansell SM, Tang H, Kurtin PJ, Koenig PA, Nowakowski GS, Nikcevich DA, Nelson GD, Yang Z, Grote DM, Ziesmer SC, Silberstein PT, Erlichman C, Witzig TE. Ansell SM, et al. Leukemia. 2012 May;26(5):1046-52. doi: 10.1038/leu.2011.297. Epub 2011 Oct 21. Leukemia. 2012. PMID: 22015775 Free PMC article. Clinical Trial.

2

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Ansell SM, et al. J Clin Oncol. 1997 Jun;15(6):2296-301. doi: 10.1200/JCO.1997.15.6.2296. J Clin Oncol. 1997. PMID: 9196143

3

Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index.

Ansell SM, Kurtin PJ, Stenson M, Habermann TM, Greipp PR, Therneau TM, Witzig TE. Ansell SM, et al. Leuk Lymphoma. 1999 Aug;34(5-6):529-37. doi: 10.3109/10428199909058480. Leuk Lymphoma. 1999. PMID: 10492076

4

Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Ansell SM, et al. J Clin Oncol. 2001 Feb 1;19(3):720-6. doi: 10.1200/JCO.2001.19.3.720. J Clin Oncol. 2001. PMID: 11157023

5

Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis.

Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Kanelli S, et al. Among authors: ansell sm. Leuk Lymphoma. 2001 Nov-Dec;42(6):1329-37. doi: 10.3109/10428190109097760. Leuk Lymphoma. 2001. PMID: 11911416 Clinical Trial.

6

Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells.

Arendt BK, Velazquez-Dones A, Tschumper RC, Howell KG, Ansell SM, Witzig TE, Jelinek DF. Arendt BK, et al. Among authors: ansell sm. Leukemia. 2002 Oct;16(10):2142-7. doi: 10.1038/sj.leu.2402714. Leukemia. 2002. PMID: 12357369

7

Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.

Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ, Janney CA, Zheng W, Potter JD, Sellers TA, Folsom AR. Cerhan JR, et al. Among authors: ansell sm. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1466-71. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12433728

8

Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma.

Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF, Fielding A. Ansell SM, et al. Leukemia. 2004 Mar;18(3):616-23. doi: 10.1038/sj.leu.2403281. Leukemia. 2004. PMID: 14749704

9

A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.

Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. Dispenzieri A, et al. Among authors: ansell sm. Leukemia. 2005 Jan;19(1):118-25. doi: 10.1038/sj.leu.2403575. Leukemia. 2005. PMID: 15526021 Clinical Trial.

10

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.

Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, Gastineau DA, Gertz MA, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ. Buadi FK, et al. Among authors: ansell sm. Bone Marrow Transplant. 2006 Jun;37(11):1017-22. doi: 10.1038/sj.bmt.1705371. Bone Marrow Transplant. 2006. PMID: 16633361

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

571 results

Search Page